S&P Futures
4,274.50 -2.25 (-0.05%) Dow Futures
33,944.00 -19.00 (-0.06%) Nasdaq Futures
13,482.50 -10.75 (-0.08%) Russell 2000 Futures
1,991.30 +2.20 (+0.11%) Crude Oil
89.27 +1.16 (+1.32%) Gold
1,779.30 +2.60 (+0.15%)
NASDAQ Biotechnology (^NBI)
| Previous Close | 4,224.02 |
| Open | 4,179.02 |
| Volume |
| Day's Range | 4,126.48 - 4,199.78 |
| 52 Week Range | 3,323.42 - 5,459.84 |
| Avg. Volume | 488,580 |
- GlobeNewswire
Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates
Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi) Initial Phase 1b data for HERKULES-1 and Phase 1 data for FLAGSHP-1 expected in H2 2022 Robust balance sheet with cash of $459 million SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer
- Yahoo Finance
BofA on Moderna: upgrading to ‘neutral’ on the ‘Tesla of biotech’
Bank of America upgraded its rating on pharma and biotech company Moderna from “underperform” to “neutral” along with a new price target of $180 (up from $135) according to a recent BofA Global Research report. BofA cited a “more reasonable valuation” that has come about as being the main reason for the upgrade.
- GlobeNewswire
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the Company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open today, Monday, December 20, 2021. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified
